Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 7/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.79 |
| ▸ | LMNA | P02545 | 5/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.73 |
| ▸ | PGR | P06401 | 4/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.73 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | AR | P10275 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | APEX1 | P27695 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9654452 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL17884670 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL13657566 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL17665286 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL3764416 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL19715951 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL1122877 | 1.00 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL11856116 | 0.92 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL11856120 | 0.92 | HIF1A (0.79) | HIF1ACYP3A4LMNAALDH1A1NR3C1 | |
| SCHEMBL11845795 | 0.91 | CYP3A4 (0.77) | HIF1ACYP3A4LMNAALDH1A1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1489 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12529704-B2 | Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2026-01-20 | — | — | US | claimed |
| EP-4178579-B1 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AS GLUCOCORTICOID-SPARING AGENT | METRIOPHARM AG (CH) | 2025-02-12 | — | — | EP | claimed |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2024-11-14 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| EP-4398930-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | Integrated Nanotherapeutics Inc. (CA) | 2024-07-17 | — | — | EP | claimed |
| US-20240165130-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-05-23 | — | — | US | claimed |
| EP-4312991-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | The Regents Of The University Of Michigan (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230420110-A1 | METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, MATCHING TO EXISTING MEDICATIONS AND NEW METHODS OF USING DRUGS, AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-12-28 | — | — | US | claimed |
| EP-4247259-A1 | METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, MATCHING TO EXISTING MEDICATIONS AND NEW METHODS OF USING DRUGS, AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS | Indiana University Research and Technology Corporation (US) | 2023-09-27 | — | — | EP | claimed |
| US-20230241060-A1 | GLUCOCORTICOID-SPARING AGENT | METRIOPHARM AG (CH) | 2023-08-03 | — | — | US | claimed |
| WO-2001015744-A9 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | BRIGHAM & WOMENS HOSPITAL (US) | 2002-09-26 | — | — | WO | claimed |
| EP-1212101-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2002-05-30 | — | — | US | claimed |
| EP-1140021-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2001-10-10 | — | — | EP | claimed |
| WO-2001015744-A1 | SYSTEMIC INFLAMMATORY MARKERS AS DIAGNOSTIC TOOLS IN THE PREVENTION OF ATHEROSCLEROTIC DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-1049471-A1 | COMPOSITIONS AND METHODS FOR TREATING ATOPIC DERMATITIS, ANGIOEDEMA AND OTHER DISORDERS USING ANTIHISTAMINES AND GLUCOCORTICOIDS | SCHERING CORPORATION (US) | 2000-11-08 | — | — | EP | claimed |
| WO-2000051605-A1 | COMPOSITIONS AND METHODS FOR TREATING ATOPIC DERMATITIS, ANGIOEDEMA AND OTHER DISORDERS USING ANTIHISTAMINES AND GLUCOCORTICOIDS | SCHERING CORPORATION (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000038653-A1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG. (DE) | 2000-07-06 | — | — | WO | claimed |
| EP-0186948-B1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 17ALPHA-HYDROXYPROGESTERONES AND CORTICOIDS FROM AN ENOL STEROID | THE UPJOHN COMPANY (US) | 1989-01-25 | — | — | EP | claimed |
| EP-0186948-A1 | Process and intermediates for the preparation of 17alpha-hydroxyprogesterones and corticoids from an enol steroid | THE UPJOHN COMPANY (US) | 1986-07-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165130-A1 | COMPOSITE DRUG PARTICLES AND USES THEREOF | LIPC, LIPA, FABP4 | HIF1A 4001/4885CYP3A4 193/4885LMNA 839/4885 |
| US-12529704-B2 | Methods for objective assessment of stress, early detection of risk for stress disorders, matching individuals with treatments, monitoring response to treatment, and new methods of use for drugs | DDB1, DDX6, DDX21 | HIF1A 2088/4885CYP3A4 1221/4885LMNA 1608/4885 |
| US-20020064524-A1 | Formulation for topical non-invasive application in vivo | CUTA, LPO, GPX4 | HIF1A 2297/4885CYP3A4 1398/4885LMNA 3910/4885 |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | LY96, CD74, TLR9 | HIF1A 3228/4885CYP3A4 4520/4885LMNA 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.